Class information for:
Level 1: CLOPIDOGREL//PRASUGREL//TICAGRELOR

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
418 3425 38.7 88%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
202 20434 CLOPIDOGREL//PRASUGREL//ASPIRIN RESISTANCE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 CLOPIDOGREL Author keyword 960 53% 37% 1258
2 PRASUGREL Author keyword 520 77% 10% 353
3 TICAGRELOR Author keyword 343 74% 7% 256
4 CLOPIDOGREL RESISTANCE Author keyword 104 76% 2% 73
5 CANGRELOR Author keyword 85 75% 2% 61
6 PLATELET REACTIVITY Author keyword 76 48% 3% 116
7 THIENOPYRIDINE Author keyword 63 55% 2% 78
8 AZD6140 Author keyword 62 92% 1% 24
9 ANTIPLATELET THERAPY Author keyword 60 26% 6% 200
10 P2Y12 Author keyword 42 47% 2% 65

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class		 LCSH search Wikipedia search
1 CLOPIDOGREL 960 53% 37% 1258 Search CLOPIDOGREL Search CLOPIDOGREL
2 PRASUGREL 520 77% 10% 353 Search PRASUGREL Search PRASUGREL
3 TICAGRELOR 343 74% 7% 256 Search TICAGRELOR Search TICAGRELOR
4 CLOPIDOGREL RESISTANCE 104 76% 2% 73 Search CLOPIDOGREL+RESISTANCE Search CLOPIDOGREL+RESISTANCE
5 CANGRELOR 85 75% 2% 61 Search CANGRELOR Search CANGRELOR
6 PLATELET REACTIVITY 76 48% 3% 116 Search PLATELET+REACTIVITY Search PLATELET+REACTIVITY
7 THIENOPYRIDINE 63 55% 2% 78 Search THIENOPYRIDINE Search THIENOPYRIDINE
8 AZD6140 62 92% 1% 24 Search AZD6140 Search AZD6140
9 ANTIPLATELET THERAPY 60 26% 6% 200 Search ANTIPLATELET+THERAPY Search ANTIPLATELET+THERAPY
10 P2Y12 42 47% 2% 65 Search P2Y12 Search P2Y12

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ASPIRIN TREATED PATIENTS 310 95% 3% 106
2 STENT THROMBOSIS 306 60% 10% 330
3 OF FUNCTION POLYMORPHISM 264 77% 5% 179
4 OF CARE ASSAY 257 86% 4% 132
5 PLATELET REACTIVITY 221 53% 8% 289
6 PLATELET INHIBITION 219 57% 8% 257
7 ANTIPLATELET THERAPY 211 27% 20% 680
8 PRASUGREL 189 55% 7% 240
9 CLOPIDOGREL 177 21% 22% 744
10 HIGH DOSE CLOPIDOGREL 151 95% 2% 52

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Novel antiplatelet agents in acute coronary syndrome 2015 8 153 69%
Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding 2013 76 73 88%
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis 2010 345 35 86%
Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy Systematic Review 2015 2 42 98%
CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis 2011 181 50 64%
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel 2012 57 41 85%
Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review 2013 24 66 89%
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans 2010 148 93 75%
Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis 2013 20 24 88%
Clopidogrel-Drug Interactions 2011 65 80 96%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SINAI THROMBOSIS 30 54% 1.1% 39
2 HEARTDRUG S 21 54% 0.8% 27
3 TIMI STUDY GRP 21 21% 2.7% 91
4 MED JACKSONVILLE 21 28% 1.8% 62
5 HOP UNIV NORD 17 79% 0.3% 11
6 ST ANTONIUS PLATELET FUNCT 15 77% 0.3% 10
7 UMRS 608 12 75% 0.3% 9
8 UPPSALA CLIN 8 13% 1.8% 60
9 MED CARDIOL 5 8 100% 0.1% 5
10 UNITA MED 3 6 48% 0.3% 10

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000249923 ASPIRIN RESISTANCE//PFA 100//THROMBOSTAT
2 0.0000165301 IST MED INTERNA VASCOLARE//AALENS MODEL//ADJUSTED SURVIVAL
3 0.0000086544 CILOSTAZOL//CLIN PHARMACOKINET PHARMACODYNAM METAB//CAS 73963 72 1
4 0.0000080861 TRANSRADIAL APPROACH//TRANSRADIAL//BIVALIRUDIN
5 0.0000080183 TICLOPIDINE//TICLOPIDINE HYDROCHLORIDE//PCA 4230
6 0.0000078431 NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME//TERRENCE DONNELLY HEART//CANADIAN HEART
7 0.0000076988 EPTIFIBATIDE//TIROFIBAN//ABCIXIMAB
8 0.0000075027 BRIDGING ANTICOAGULATION//BRIDGING THERAPY//BLOOD THINNERS
9 0.0000060615 ACT STUDY//ASPIRIN DOSE//ANTIOXIDANT DEFENSE MECHANISM
10 0.0000058655 TRANSIENT ISCHEMIC ATTACK//ABCD2 SCORE//TIA